Interestingly, glial cells and glutamate transporter expression were not shown to be associated with the cognitive impairment seen in younger Adrβ3KO mice, but the MS protocol could decrease GFAP and Iba1 expression in the HC, which might have contributed to reverting Adrβ3KO-related cognitive decline. The gene discussed is GFAP; the disease is Cognitive impairment.